Penumbra Inc (PEN)

$191.68

+0.85

(+0.45%)

Market is closed - opens 7 PM, 16 Jul 2024

Performance

  • $188.35
    $193.58
    $191.68
    downward going graph

    1.74%

    Downside

    Day's Volatility :2.7%

    Upside

    0.98%

    downward going graph
  • $170.59
    $323.34
    $191.68
    downward going graph

    11.0%

    Downside

    52 Weeks Volatility :47.24%

    Upside

    40.72%

    downward going graph

Returns

PeriodPenumbra IncSector (Health Care)Index (Russel 2000)
3 Months
-9.21%
7.0%
0.0%
6 Months
-27.46%
5.5%
0.0%
1 Year
-39.13%
12.6%
0.0%
3 Years
-23.89%
15.6%
-19.2%

Highlights

Market Capitalization
7.0B
Book Value
$31.05
Earnings Per Share (EPS)
2.39
PE Ratio
75.09
PEG Ratio
-62.27
Wall Street Target Price
266.29
Profit Margin
8.52%
Operating Margin TTM
4.34%
Return On Assets TTM
4.03%
Return On Equity TTM
8.38%
Revenue TTM
1.1B
Revenue Per Share TTM
28.44
Quarterly Revenue Growth YOY
15.4%
Gross Profit TTM
535.2M
EBITDA
121.8M
Diluted Eps TTM
2.39
Quarterly Earnings Growth YOY
0.27
EPS Estimate Current Year
2.86
EPS Estimate Next Year
3.84
EPS Estimate Current Quarter
0.38
EPS Estimate Next Quarter
0.61

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Penumbra Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
15
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 38.92%

Current $191.68
Target $266.29

Company Financials

FY18Y/Y Change
Revenue
444.9M
↑ 33.31%
Net Income
6.6M
↑ 41.74%
Net Profit Margin
1.48%
↑ 0.08%
FY19Y/Y Change
Revenue
547.4M
↑ 23.03%
Net Income
48.5M
↑ 634.1%
Net Profit Margin
8.85%
↑ 7.37%
FY20Y/Y Change
Revenue
560.4M
↑ 2.38%
Net Income
-19.3M
↓ 139.74%
Net Profit Margin
-3.44%
↓ 12.29%
FY21Y/Y Change
Revenue
747.6M
↑ 33.4%
Net Income
2.6M
↓ 113.62%
Net Profit Margin
0.35%
↑ 3.79%
FY22Y/Y Change
Revenue
847.1M
↑ 13.32%
Net Income
-2.0M
↓ 176.32%
Net Profit Margin
-0.24%
↓ 0.59%
FY23Y/Y Change
Revenue
1.1B
↑ 24.95%
Net Income
91.0M
↓ 4643.16%
Net Profit Margin
8.59%
↑ 8.83%
Q4 FY22Q/Q Change
Revenue
221.2M
↑ 3.53%
Net Income
3.9M
↓ 270.72%
Net Profit Margin
1.75%
↑ 2.81%
Q1 FY23Q/Q Change
Revenue
241.4M
↑ 9.12%
Net Income
8.6M
↑ 120.84%
Net Profit Margin
3.55%
↑ 1.8%
Q2 FY23Q/Q Change
Revenue
261.5M
↑ 8.33%
Net Income
19.0M
↑ 121.44%
Net Profit Margin
7.25%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
270.9M
↑ 3.61%
Net Income
9.2M
↓ 51.4%
Net Profit Margin
3.4%
↓ 3.85%
Q4 FY23Q/Q Change
Revenue
284.7M
↑ 5.07%
Net Income
54.2M
↑ 488.43%
Net Profit Margin
19.05%
↑ 15.65%
Q1 FY24Q/Q Change
Revenue
278.7M
↓ 2.12%
Net Income
11.0M
↓ 79.71%
Net Profit Margin
3.95%
↓ 15.1%
FY18Y/Y Change
Total Assets
515.0M
↑ 8.04%
Total Liabilities
92.6M
↑ 21.42%
FY19Y/Y Change
Total Assets
665.9M
↑ 29.3%
Total Liabilities
180.3M
↑ 94.71%
FY20Y/Y Change
Total Assets
823.0M
↑ 23.59%
Total Liabilities
185.2M
↑ 2.72%
FY21Y/Y Change
Total Assets
1.2B
↑ 51.19%
Total Liabilities
290.3M
↑ 56.77%
FY22Y/Y Change
Total Assets
1.4B
↑ 10.18%
Total Liabilities
372.0M
↑ 28.14%
FY23Y/Y Change
Total Assets
1.6B
↑ 13.53%
Total Liabilities
377.4M
↑ 1.43%
Q4 FY22Q/Q Change
Total Assets
1.4B
↑ 3.73%
Total Liabilities
372.0M
↑ 6.95%
Q1 FY23Q/Q Change
Total Assets
1.4B
↑ 1.78%
Total Liabilities
370.8M
↓ 0.32%
Q2 FY23Q/Q Change
Total Assets
1.4B
↑ 2.67%
Total Liabilities
366.0M
↓ 1.31%
Q3 FY23Q/Q Change
Total Assets
1.5B
↑ 2.5%
Total Liabilities
364.2M
↓ 0.48%
Q4 FY23Q/Q Change
Total Assets
1.6B
↑ 5.99%
Total Liabilities
377.4M
↑ 3.6%
Q1 FY24Q/Q Change
Total Assets
1.6B
↑ 1.51%
Total Liabilities
376.3M
↓ 0.28%
FY18Y/Y Change
Operating Cash Flow
28.8M
↑ 127.0%
Investing Cash Flow
-385.0K
↓ 99.5%
Financing Cash Flow
-9.8M
↓ 109.41%
FY19Y/Y Change
Operating Cash Flow
26.7M
↓ 7.48%
Investing Cash Flow
-12.7M
↑ 3201.56%
Financing Cash Flow
-9.0M
↓ 8.72%
FY20Y/Y Change
Operating Cash Flow
-33.2M
↓ 224.73%
Investing Cash Flow
-104.1M
↑ 719.36%
Financing Cash Flow
134.9M
↓ 1605.94%
FY21Y/Y Change
Operating Cash Flow
9.5M
↓ 128.58%
Investing Cash Flow
-21.7M
↓ 79.13%
Financing Cash Flow
836.0K
↓ 99.38%
FY22Y/Y Change
Operating Cash Flow
-55.7M
↓ 685.78%
Investing Cash Flow
54.8M
↓ 352.08%
Financing Cash Flow
11.6M
↑ 1290.19%
Q4 FY22Q/Q Change
Operating Cash Flow
1.3M
↓ 110.36%
Investing Cash Flow
54.8M
↑ 459.88%
Financing Cash Flow
5.7M
↓ 1051.08%
Q1 FY23Q/Q Change
Operating Cash Flow
13.1M
↑ 881.97%
Investing Cash Flow
10.7M
↓ 80.45%
Financing Cash Flow
1.4M
↓ 76.01%
Q2 FY23Q/Q Change
Operating Cash Flow
17.1M
↑ 30.24%
Investing Cash Flow
-6.7M
↓ 162.28%
Financing Cash Flow
8.7M
↑ 531.83%
Q3 FY23Q/Q Change
Operating Cash Flow
30.8M
↑ 80.38%
Investing Cash Flow
-40.4M
↑ 504.95%
Financing Cash Flow
212.0K
↓ 97.56%

Technicals Summary

Sell

Neutral

Buy

Penumbra Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Penumbra Inc
Penumbra Inc
1.87%
-27.46%
-39.13%
-23.89%
10.48%
Stryker Corporation
Stryker Corporation
-1.55%
7.98%
13.65%
32.02%
65.15%
Boston Scientific Corp.
Boston Scientific Corp.
1.97%
28.95%
47.67%
84.27%
83.02%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.74%
22.98%
-1.79%
-14.43%
43.0%
Abbott Laboratories
Abbott Laboratories
0.74%
-8.39%
-2.6%
-10.66%
24.35%
Medtronic Plc
Medtronic Plc
-2.5%
-9.93%
-10.1%
-37.82%
-21.91%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Penumbra Inc
Penumbra Inc
75.09
75.09
-62.27
2.86
0.08
0.04
NA
31.05
Stryker Corporation
Stryker Corporation
38.74
38.74
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.8
64.8
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
40.02
40.02
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.2
32.2
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.92
27.92
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Penumbra Inc
Penumbra Inc
Buy
$7.0B
10.48%
75.09
8.52%
Stryker Corporation
Stryker Corporation
Buy
$129.3B
65.15%
38.74
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$113.4B
83.02%
64.8
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$56.0B
43.0%
40.02
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.3B
24.35%
32.2
13.96%
Medtronic Plc
Medtronic Plc
Buy
$98.8B
-21.91%
27.92
11.36%

Insights on Penumbra Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 284.67M → 278.65M (in $), with an average decrease of 2.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 54.21M → 11.00M (in $), with an average decrease of 79.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.5% return, outperforming this stock by 85.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 84.3% return, outperforming this stock by 108.2%

Institutional Holdings

  • FMR Inc

    14.98%
  • BlackRock Inc

    10.48%
  • Vanguard Group Inc

    9.52%
  • T. Rowe Price Associates, Inc.

    7.81%
  • State Street Corporation

    3.11%
  • Capital Research Global Investors

    2.92%

Company Information

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.

Organization
Penumbra Inc
Employees
4200
CEO
Mr. Adam Elsesser
Industry
Health Technology

FAQs